1 Min Read
May 17 (Reuters) - MabVax Therapeutics Holdings Inc :
* MABVAX THERAPEUTICS RECEIVES U.S. PATENT FOR FULLY HUMAN ANTIBODIES TARGETING THE ANTIGEN GD2 EXPRESSED ON SARCOMA, MELANOMA, AND NEUROBLASTOMA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.